Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTao WangCMCaridad Martinez

Discussion

Loading...

Member takes

Overview

Phase 1 trial of cll-1 car t-cells demonstrated feasibility and safety in adolescents and adults with acute myeloid leukemia, indicating potential for hematopoietic stem cell transplantation.

Key Points

  • Cll-1 car t-cells induced a complete response in 2 patients with acute myeloid leukemia, allowing for hemotopoietic stem cell transplantation.
  • Fifty-seven percent of patients experienced cytokine release syndrome, while a notable number faced dose limiting toxicity.
  • Observational analysis of Cll-1 car t-cells was conducted across multiple dose levels after lymphodepleting chemotherapy.
  • Requires further investigation to fully understand the impact of cll-1 car t-cells on treating high-risk acute myeloid leukemia.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddafhttps://doi.org/10.1182/blood-2025-2372
View Full Paper
Ask AI
Bookmark
Share